title: Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
abstract: BACKGROUND
  Simpler and less toxic antiretroviral strategies are needed to maximize treatment compliance without sacrificing potency, at least for drug-experienced HIV-infected patients currently on regimens containing protease inhibitors (PIs). Small nonrandomized studies have suggested a beneficial role of PI-sparing regimens on lipodystrophy.
  
  
  OBJECTIVE
  To assess the virologic, immunologic, and clinical benefit of switching the PI to nevirapine in patients with HIV-associated lipodystrophy and sustained viral suppression before entry in the study.
  
  
  METHODS
  Open-labeled, prospective, randomized, multicenter study.
  
  
  METHODS
  Seven reference inpatient centers for HIV/AIDS in Spain.
  
  
  METHODS
  One hundred six HIV-infected adults with clinically evident lipodystrophy who sustained HIV-RNA suppression for at least 6 months with PI-containing antiretroviral combinations.
  
  
  METHODS
  Replacement of the PI with nevirapine during 48 weeks (Group A) versus continuing the prior PI (Group B).
  
  
  METHODS
  Several virologic and immunologic analyses, standard and specific biochemical tests, and anthropometric and dual X-ray absorptiometry measurements.
  
  
  RESULTS
  At week 48, an HIV-1 RNA level <400 copies/ml was maintained in 79% and 77% of patients in Groups A and B, respectively, whereas 74% and 72% of patients had viral load levels <50 copies/ml. Absolute CD4+ counts significantly increased in both groups compared with baseline values, and a significant decrease in CD38+CD8+ cells was observed in Group A (p <.01) but not in group B. Overall, no significant changes in anthropometric or body shape measurements were found after 48 weeks. Fasting total cholesterol and triglyceride levels decreased in Group A (but not in Group B) compared with baseline values (p <.05), although no significant differences were seen between groups at the end of the study. Subjects in Group A reported a better quality of life (QOL) index than controls (p <.001), with the main reason reported being the greater simplicity of the new drug regimen.
  
  
  CONCLUSIONS
  Protease inhibitor-sparing regimens, including nevirapine, seem to be an effective alternative for PI-experienced patients. Nevirapine-based triple therapies allow maintained control of HIV-1 RNA levels and improve the immunologic response at 48 weeks of follow-up in patients with prior sustained virologic suppression. The switch to nevirapine significantly improved the lipidic profile in Group A, although there were no differences between groups at the end of the study. Additionally, no significant changes were seen in terms of lipodystrophy-related body shape changes 1 year after the PI substitution. Finally, nevirapine-containing regimens have a simpler dosing schedule, and this facilitates high adherence and improves QOL.
authors.affiliation: "IrsiCaixa" Foundation, Retrovirology Laboratory and HIV Unit, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. lruiz@ns.hugtip.scs.es
authors.forename: L
authors.initials: L
authors.lastname: Ruiz
authors.forename: E
authors.initials: E
authors.lastname: Negredo
authors.forename: P
authors.initials: P
authors.lastname: Domingo
authors.forename: R
authors.initials: R
authors.lastname: Paredes
authors.forename: E
authors.initials: E
authors.lastname: Francia
authors.forename: M
authors.initials: M
authors.lastname: Balagué
authors.forename: S
authors.initials: S
authors.lastname: Gel
authors.forename: A
authors.initials: A
authors.lastname: Bonjoch
authors.forename: C R
authors.initials: CR
authors.lastname: Fumaz
authors.forename: S
authors.initials: S
authors.lastname: Johnston
authors.forename: J
authors.initials: J
authors.lastname: Romeu
authors.forename: J
authors.initials: J
authors.lastname: Lange
authors.forename: B
authors.initials: B
authors.lastname: Clotet
mesh_terms: D000328:Adult; D000886:Anthropometry; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D001823:Body Composition / Q000187:drug effects; D018791:CD4 Lymphocyte Count; D002784:Cholesterol / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D008060:Lipodystrophy / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D018655:Lymphocyte Count; D008297:Male; D019829:Nevirapine / Q000627:therapeutic use*; D010349:Patient Compliance; D011446:Prospective Studies; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011788:Quality of Life; D012367:RNA, Viral / Q000097:blood; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D011480:Protease Inhibitors; D012367:RNA, Viral; D014280:Triglycerides; D002784:Cholesterol; D019829:Nevirapine